Business
Quarterly Operational Update
Quarterly Operational Update.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n \n ValiRx PLC (\"ValiRx\" or the \"Company\")\n \n \n \n \n Quarterly Operational Update\n \n \n \n London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, today provides an update on operational activities.\n \n \n \n Inaphaea BioLabs\n \n \n \n Following the launch of our wholly owned subsidiary Inaphaea BioLabs Limited (\"Inaphaea\") announced on 1 March 2023, its facility in MediCity (Nottingham) has been fitted out to conduct a range of cell-based assays. The Lead Scientist and Senior Scientist are working full time in the lab to validate the equipment and assays, supported by the ValiRx senior scientific management team.\n \n \n Dr Andrew Carnegie has commenced full time employment with Inaphaea to develop the commercial strategy, including surveying the market needs, assessing innovative technology and securing business opportunities. \n \n \n Initial cell-based assays services are expected to be operational during Q2 2023. Inaphaea is also investigating additional innovative technologies to in-license, which will enhance the data generation capabilities of Inaphaea as a translational contract research organisation (tCRO™).\n \n \n Inaphaea will be attending BioTrinity in London, an OBN event, in April 2023 as an exhibitor to market the services and conduct conversations with potential customers.\n \n \n \n Evaluation Projects\n \n \n \n Evaluation Agreement with Hokkaido University (Japan) (Announced: 16 December 2021, extension announced 6 December 2022)\n \n \n The extension of the Evaluation Agreement with Hokkaido University has allowed ValiRx to continue experimental testing. Product development has continued and a supply of material in a suitable salt form has been achieved. Pre-formulation assays are underway and biological testing in Inaphaea's lab is scheduled to commence in Q2 2023.\n \n \n Evaluation Agreement with the University of Barcelona (Announced: 14 February 2022)\n \n \n This evaluation project has completed the 12 months scheduled for scientific evaluation which included expansion of the IP protection, computational binding assays, chemical synthesis, in-vitro and in-vivo biological testing. Discussions are in process with the University of Barcelona to confirm the next steps for the technology wh...